1887

Chapter 3 : Mechanisms of Quinolone Resistance

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Mechanisms of Quinolone Resistance, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap03-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap03-2.gif

Abstract:

This chapter reviews the mechanisms of quinolone resistance. Initial studies of resistant clinical isolates of prior to the recognition of the role of topoisomerase IV in resistance commonly had GyrA mutations, but when ParC and ParE were also evaluated, GyrA quinolone resistance mutations were not found in the absence of mutations in topoisomerase IV. The strongest genetic data for the secondary role of topoisomerase IV in quinolone resistance is from , in which mutations in ParC or ParE were shown to contribute to resistance only in the presence of mutant GyrA.. The largest body of information concerning the role of topoisomerase IV in quinolone resistance in gram-positive bacteria comes from studies of and . It seems likely that the role of the Mar and Sox regulons and the AcrAB efflux pump in quinolone resistance in serovar will be similar to that in . Although all four known efflux systems in cause increases in resistance to quinolones when overexpressed, quinolone congeners differ in the extent to which they are affected by each system, and use of different quinolones in resistance selections results in differential selection of mutants overexpressing these systems. The two best-studied systems that effect quinolone resistance are NorA of and Bmr and Bit of , but additional examples are being identified and studied in other gram-positive bacteria.

Citation: Hooper D. 2003. Mechanisms of Quinolone Resistance, p 41-67. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch3
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap3
1. Ackermann, G.,, Y. J. Tang,, R. Kueper,, P. Heisig,, A. C. Rodloff,, J. Silva Jr.,, and S. H. Cohen. 2001. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 45: 2348 2353.
2. Aeschlimann, J. R.,, L. D. Dresser,, G. W. Kaatz,, and M. J. Rybak. 1999. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 335 340.
3. Ahmed, M.,, C. M. Borsch,, S. S. Taylor,, N. Vazquez-Laslop,, and A. A. Neyfakh. 1994. A protein that activates expression of a multidrug efflux transporter upon binding the transporter substrates J. Biol. Chem. 269: 28506 28513.
4. Ahmed, M.,, L. Lyass,, P. N. Markham,, S. S. Taylor,, N. Vazquez-Laslop,, and A. A. Neyfakh. 1995. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. Bacteriol. 177: 3904 3910.
5. Akasaka, T.,, M. Tanaka,, A. Yamaguchi,, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45: 2263 2268.
6. Alangaden, G. J.,, E. K. Manavathu,, S. B. Vakulenko,, N. M. Zvonok,, and S. A. Lerner. 1995. Characterization of fluoroquinolone- resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39: 1700 1703.
7. Alekshun, M. N.,, and S. B. Levy. 1997. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob. Agents Chemother. 41: 2067 2075.
8. Alonso, A.,, and J. L. Martinez. 2000. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 44: 3079 3086.
9. Alonso, A.,, and J. L. Martinez. 2001. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia . Antimicrob. Agents Chemother. 45: 1879 1881.
10. Alovero, F. L.,, X . S. Pan,, J. E. Morris,, R. H. Manzo,, and L. M. Fisher. 2000. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. 44: 320 325.
11. Andersen, J.,, N. Delihas,, K. Ikenaka,, P. J. Green,, O. Pines,, O. Ilercil,, and M. Inouye. 1987. The isolation and characterization of RNA coded by the micF gene in Escherichia coli . Nucleic Acids Res. 15: 2089 2101.
12. Ariza, R. R.,, S. P. Cohen,, N. Bachhawat,, S. B. Levy,, and B. Demple. 1994. Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli. J. Bacteriol. 176: 143 148.
13. Bachoual, R.,, L. Dubreuil,, C. J. Soussy,, and J. Tankovic. 2000. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 44: 1842 1845.
14. Bagel, S.,, V. Htillen,, B. Wiedemann,, and P. Heisig. 1999. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob. Agents Chemother. 43: 868 875.
15. Balague, C.,, and E. G. Vescovi. 2001. Activation of multiple antibiotic resistance in uropathogenic Escherichia coli strains by aryloxoalcanoic acid compounds. Antimicrob. Agents Chemother. 45: 1815 1822.
16. Baranova, N. N.,, and A. A. Neyfakh. 1997. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41: 1396 1398.
17. Barnard, F. M.,, and A. Maxwell. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser8 3 and Asp8 7. Antimicrob. Agents Chemother. 45: 1994 2000.
18. Bast, D. J.,, J. C. S. De Azavedo,, T. Y. Tarn,, L. Kilburn,, C. Duncan,, L. A. Mandell,, R. J. Davidson,, and D. E. Low. 2001. Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 2631 2634.
19. Bast, D. J.,, D. E. Low,, C. L. Duncan,, L. Kilburn,, L. A. Mandell,, R. J. Davidson,, and J. C. S. De Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44: 3049 3054.
20. Bebear, C. M.,, A. Charron,, J. M. Bove,, C. Bebear,, and J. Renaudin. 1998. Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis . Antimicrob. Agents Chemother. 42: 2024 2031.
21. Bebear, C. M.,, H. Renaudin,, A. Charron,, J. M. Bove,, C. Bebear,, and J. Renaudin. 1998. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob. Agents Chemother. 42: 2304 2311.
22. Bebear, C. M.,, J. Renaudin,, A. Charron,, H. Renaudin,, B. de Barbeyrac,, T. Schaeverbeke,, and C. Bebear. 1999. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob. Agents Chemother. 43: 954 956.
23. Belland, R. J.,, S. G. Morrison,, C. Ison,, and W. M. Huang. 1994. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 14: 371 380.
24. Berger, J. M. 1998. Type II DNA topoisomerases. Curr. Opin. Struct. Biol. 8: 26 32.
25. Berger, J. M.,, S. J. Gamblin,, S. C. Harrison,, and J. C. Wang. 1996. Structure and mechanism of DNA topoisomerase II. Nature 379: 225 232.
26. Berger, J. M.,, and J. C. Wang. 1996. Recent developments in DNA topoisomerase II structure and mechanism. Curr. Opin. Struct. Biol. 6: 84 90.
27. Blanche, F.,, B. Cameron,, F. X . Bernard,, L. Maton,, B. Manse,, L. Ferrero,, N. Ratet,, C. Lecoq,, A. Goniot,, D. Bisch,, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40: 2714 2720.
28. Reference deleted.
29. Breines, D. M.,, S. Ouabdesselam,, E. Y. Ng,, J. Tankovic,, S. Shah,, C. J. Soussy,, and D. C. Hooper. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41: 175 179.
30. Brenwald, N. P.,, M. J. Gill,, and R. Wise. 1997. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J. Antimicrob. Chemother. 40: 458 460.
31. Brenwald, N. P.,, M. J. Gill,, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinoloneresistant clinical isolates of Streptococcus pneumoniae . Antimicrob. Agents Chemother. 42: 2032 2035.
32. Brisse, S.,, A. C. Fluit,, U. Wagner,, P. Heisig,, D. Milatovic,, J. Verhoef,, S. Scheming,, K. Kohrer,, and F. J. Schrnitz. 1999. Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob. Agents Chemother. 43: 2513 2516.
33. Brisse, S.,, D. Milatovic,, A. C. Fluit,, J. Verhoef,, N. Martin,, S. Scheming,, K. Kohrer,, and F. J. Schmitz. 1999. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob. Agents Chemother. 43: 2051 2055.
34. Brooun, A.,, S. Liu,, and K. Lewis. 2000. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 44: 640 646.
35. Broskey, J.,, K. Coleman,, M. N. Gwynn,, L. McCloskey,, C. Traini,, L. Voelker,, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae . J. Antimicrob. Chemother. 45: 95 99.
36. Cabral, J. H.,, A. P. Jackson,, C. V. Smith,, N. Shikotra,, A. Maxwell,, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388: 903 906.
37. Charvalos, E.,, Y. Tselentis,, M. M. Hamzehpour,, T. Kohler,, and J. C. Pechere. 1995. Evidence for an efflux pump in multidrug- resistant Campylobacter jejuni . Antimicrob. Agents Chemother. 39: 2019 2022.
38. Chou, J. H.,, J. T. Greenberg,, and B. Demple. 1998. Postranscriptional repression of Escherichia coli OmpF protein in response to redox stress: positive control of the micF antisense RNA by the soxRS locus. J. Bacteriol. 175: 1026 1031.
39. Chuanchuen, R.,, K. Beinlich,, T. T. Hoang,, A. Becher,, R. R. Karkhoff-Schweizer,, and H. P. Schweizer. 2001. Crossresistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-Opr J. Antimicrob. Agents Chemother. 45: 428 432.
40. Cohen, S. P.,, S. B. Levy,, J. Foulds,, and J. L. Rosner. 1993. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar -independent pathway. J. Bacteriol. 175: 7856 7862.
41. Cohen, S. P.,, L. M. McMurry,, D. C. Hooper,, J. S. Wolfson,, and S. B. Levy. 1989. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. 33: 1318 1325.
42. Cohen, S. P.,, L. M. McMurry,, and S. B. Levy. 1988. marA locus causes decreased expression of OmpF porin in multiple- antibiotic-resistant (Mar) mutants of Escherichia coli. J. Bacteriol. 170: 5416 5422.
43. Cole, S. T.,, R. Brosch,, J. Parkhill,, T. Gamier,, C. Churcher,, D. Harris,, S. V. Gordon,, K. Eiglmeier,, S. Gas,, C. E. Barry,, F. Tekaia,, K. Badcock,, D. Basham,, D. Brown,, T. Chillingworth,, R. Connor,, R. Davies,, K. Devlin,, T. Feltwell,, S. Gentles,, N. Hamlin,, S. Holroyd,, T. Hornsby,, K. Jagels,, and B. G. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537 544.
44. Cornier, J. A.,, J. A. Fralick,, and A. N. Hamood. 1998. Isolation and characterization of a putative multidrug resistance pump from Vibrio cholerae. Mol. Microbiol. 27: 63 72.
45. De Kievit, T. R.,, M. D. Parkins,, R. J. Gillis,, R. Srikumar,, H. Ceri,, K. Poole,, B. H. Iglewski,, and D. G. Storey. 2001. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 45: 1761 1770.
46. Deguchi, T.,, A. Fukuoka,, M. Yasuda,, M. Nakano,, S. Ozeki,, E. Kanematsu,, Y. Nishino,, S. Ishihara,, Y. Ban,, and Y. Kawada. 1997. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41: 699 701.
47. Deguchi, T.,, T. Kawamura,, M. Yasuda,, M. Nakano,, H. Fukuda,, H. Kato,, N. Kato,, Y. Okano,, and Y. Kawada. 1997. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Antimicrob. Agents Chemother. 41: 1609 1611.
48. Deguchi, T.,, M. Yasuda,, M. Nakano,, S. Ozeki,, T. Ezaki,, I. Saito,, and Y. Kawada. 1996. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob. Agents Chemother. 40: 1020 1023.
49. Dessus-Babus, S.,, C. M. Bebear,, A. Charron,, C. Bebear,, and B. de Barbeyrac. 1998. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinoloneresistant mutants obtained in vitro. Antimicrob. Agents Chemother. 42: 2474 2481.
50. Discotto, L. F.,, L. E. Lawrence,, K. L. Denbleyker,, and J. F. Barrett. 2001. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob. Agents Chemother. 45: 3273 3275.
51. Drlica, K.,, E. C. Engle,, and S. H. Manes. 1980. DNA gyrase on the bacterial chromosome: possibility of two levels of action. Proc. Natl. Acad. Sci. USA 77: 6879 6883.
52. Edgar, R.,, and E. Bibi. 1997. MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179: 2274 2280.
53. El Amin, N.,, S. Jalal,, and B. Wretlind. 1999. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 43: 947 949.
54. Evans, K.,, K. Passador,, R. Srikumar,, E. Tsang,, J. Nezezon,, and K. Poole. 1998. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 180: 5443 5447.
55. Ferrero, L.,, B. Cameron,, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacinresistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39: 1554 1558.
56. Ferrero, L.,, B. Cameron,, B. Manse,, D. Lagneaux,, J. Crouzet,, A. Famechon,, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13: 641 653.
57. Fitzgibbon, J. E.,, J. F. John,, J. L. Delucia,, and D. T. Dubin. 1998. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42: 2122 2124.
58. Fournier, B.,, R. Aras,, and D. C. Hooper. 2000. Expression of the multidrug resistance transporter NorA from Staphylococcus aureus is modified by a two-component regulatory system. J. Bacteriol. 182: 664 671.
59. Fournier, B.,, and D. C. Hooper. 1998. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42: 2109 2112.
60. Fournier, B.,, and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42: 121 128.
61. Fournier, B.,, and D. C. Hooper. 2000. A new two-component regulatory system involved in adhesion autolysis, and extracellular proteolytic activity of Staphylococcus aureus. J. Bacteriol. 182: 3955 3964.
62. Fournier, B.,, Q. C. Truong-Bolduc,, X. Zhang,, and D. C. Hooper. 2001. A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J. Bacteriol. 183: 2367 2371.
63. Fournier, B.,, X . Zhao,, T. Lu,, K. Drlica,, and D. C. Hooper. 2000. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus : different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 44: 2160 2165.
64. Fralick, J. A. 1996. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J. Bacteriol. 178: 5803 5805.
65. Fraser, C. M.,, S. J. Norris,, G. M. Weinstock,, O. White,, G. G. Sutton,, R. Dodson,, M. Gwinn,, E. K. Hickey,, R. Clayton,, K. A. Ketchum,, E. Sodergren,, J. M. Hardham,, M. P. McLeod,, S. Salzberg,, J. Peterson,, H. Khalak,, D. Richardson,, J. K. Howell,, M. Chidambaram,, T. Utterback,, L. McDonald,, P. Artiach,, C. Bowman,, M. D. Cotton,, and J. C. Venter. 1998. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 281: 375 388.
66. Friedman, S. M.,, T. Lu,, and K. Drlica. 2001. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 45: 2378 2380.
67. Fukuda, H.,, and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 410 412.
68. Fukuda, H.,, M. Hosaka,, S. Iyobe,, N. Gotoh,, T. Nishino,, and K. Hirai. 1995. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39: 790 792.
69. Fukuda, H.,, R. Kishii,, M. Takei,, and M. Hosaka. 2001. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1649 1653.
70. Furukawa, H.,, J. T. Tsay,, S. Jackowski,, Y. Takamura, and C O. Rock. 1993. Thiolactomycin resistance in Escherichia coli is associated with the multidrug resistance efflux pump encoded by emrAB. J. Bacteriol. 175: 3723 3729.
71. Gensberg, K.,, Y. F. Jin,, and L. J. Piddock. 1995. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol. Lett. 132: 57 60.
72. George, A. M.,, R. M. Hall,, and H. W. Stokes. 1995. Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli . Microbiology 141: 1909 1920.
73. George, A. M.,, and S. B. Levy. 1983. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. J. Bacteriol. 155: 531 540.
74. George, A. M.,, and S. B. Levy. 1983. Gene in the major cotransduction gap of the Escherichia coli K-12 linkage map required for the expression of chromosomal resistance to tetracycline and other antibiotics. J. Bacteriol. 155: 541 548.
75. Georgiou, M.,, R. Murioz,, F. Roman,, R. Canton,, R. Gomez- Lus,, J. Campos,, and A. G. de la Campa. 1996. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob. Agents Chemother. 40: 1741 1744.
76. Gill, M. J.,, N. P. Brenwald,, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 187 189.
77. Giraud, E.,, A. Cloeckaert,, D. Kerboeuf,, and E. Chaslus- Dancla. 2000. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44: 1223 1228.
78. Gonzalez, I.,, M. Georgiou,, F. Alcaide,, D. Balas,, and A. G. de la Campa. 1998. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob. Agents Chemother. 42: 2792 2798.
79. Gootz, T. D.,, R. Zaniewski,, S. Haskell,, B. Schmieder,, J. Tankovic,, D. Girard,, P. Courvalin,, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP- 99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40: 2691 2697.
80. Grinius, L. L.,, and E. B. Goldberg. 1994. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J. Biol. Chem. 269: 29998 30004.
81. Gustafson, J. E.,, P. V. Candelaria,, S. A. Fisher,, J. P. Goodridge,, T. M. Lichocik,, T. M. McWilliams,, C. T. Price,, F. G. O'Brien,, and W. B. Grubb. 1999. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 990 992.
82. Hagman, K. E.,, W. Pan,, B. G. Spratt,, J. T. Balthazar,, R. C. Judd,, and W. M. Shafer. 1995. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 141: 611 622.
83. Heaton, V. J.,, J. E. Ambler,, and L. M. Fisher. 2000. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 44: 3112 3117.
84. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40: 879 885.
85. Hiasa, H.,, D. O. Yousef,, and K. J. Marians. 1996. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J. Biol. Chem. 271: 26424 26429.
86. Hirai, K.,, H. Aoyama,, T. Irikura,, S. Iyobe,, and S. Mitsuhashi. 1986. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob. Agents Chemother. 29: 535 538.
87. Hirai, K.,, S. Suzue,, T. Irikura,, S. Iyobe,, and S. Mitsuhashi. 1987. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31: 582 586.
88. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27: S54 S63.
89. Hooper, D. C. 1999. Mechanisms of quinolone resistance. Drug Resist. Updates 2: 38 55.
90. Hooper, D. C.,, J. S. Wolfson,, K. S. Souza,, E. Y. Ng,, G. L. McHugh,, and M. N. Swartz. 1989. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob. Agents Chemother. 33: 283 290.
91. Hori, S.,, Y. Ohshita,, Y. Utsui,, and K. Hiramatsu. 1993. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37: 2278 2284.
92. Hoshino, K.,, A. Kitamura,, I. Morrissey,, K. Sato,, J. Kato,, and H. Ikeda. 1994. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38: 2623 2627.
92a. Hsieh, P. C.,, S. A. Siegel,, B. Rogers,, D. Davis,, and K. Lewis. 1998. Bacteria lacking a multidrug efflux pump: a sensitive tool for drug discovery. Proc. Natl. Acad. Sci. USA 95: 6602 6606.
93. Ince, D.,, R. Aras,, and D. C. Hooper. 1999. Mechanisms and frequency of resistance to moxifloxacin in comparison with ciprofloxacin in Staphylococcus aureus . Drugs 58: 132 133.
94. Ince, D.,, and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44: 3344 3350.
95. Ince, D.,, and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM- 1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755 2764.
96. Ishida, H.,, H. Fuziwara,, Y. Kaibori,, T. Horiuchi,, K. Sato,, and Y. Osada. 1995. Cloning of multidrug resistance gene pqrA from Proteus vulgaris . Antimicrob. Agents Chemother. 39:453-457.
97. Ito, H.,, H. Yoshida,, M. Bogaki-Shonai,, T. Niga,, H. Hattori,, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus . Antimicrob. Agents Chemother. 38: 2014 2023.
98. Jalal, S.,, O. Ciofu,, N. Hoiby,, N. Gotoh,, and B. Wretlind. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44: 710 712.
99. Janoir, C.,, E. Varon,, M. D. Kitzis,, and L. Gutmann. 2001. New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob. Agents Chemother. 45: 952 955.
100. Janoir, C.,, V. Zeller,, M. D. Kitzis,, N. J. Moreau,, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40: 2760 2764.
101. Kaatz, G. W.,, and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39: 2650 2655.
102. Kanematsu, E.,, T. Deguchi,, M. Yasuda,, T. Kawamura,, Y. Nishino,, and Y. Kawada. 1998. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 42: 433 435.
103. Kern, W. V.,, M. Oethinger,, A. S. Jellen-Ritter,, and S. B. Levy. 2000. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44: 814 820.
104. Khodursky, A. B.,, E. L. Zechiedrich,, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli . Proc. Natl. Acad. Sci. USA 92: 11801 11805.
105. Kocagoz, T.,, C. J. Hackbarth,, I. Unsal,, E. Y . Rosenberg,, H. Nikaido,, and H. F. Chambers. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone- resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40: 1768 1774.
106. Kohler, T.,, M. Kok,, M. Michea-Hamzehpour,, P. Plesiat,, N. Gotoh,, T. Nishino,, L. K. Curty,, and J. C. Pechere. 1996. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40: 2288 2290.
107. Kohler, T.,, M. Michea-Hamzehpour,, U. Henze,, N. Gotoh,, L. Curty,, and J. C. Pechere. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23: 345 354.
108. Kohler, T.,, M. Michea-Hamzehpour,, P. Plesiat,, A. L. Kahr,, and J. C. Pechere. 1997. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41: 2540 2543.
109. Kohler, T.,, C. Van Delden,, L. K. Curty,, M. M. Hamzehpour,, and J. C. Pechere. 2001. Overexpression of the MexEFOprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa. J. Bacteriol. 183: 5213 5222.
110. Korten, V.,, W. M. Huang,, and B. E. Murray. 1994. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis . Antimicrob. Agents Chemother. 38: 2091 2094.
111. Koutsolioutsou, A.,, E. A. Martins,, D. G. White,, S. B. Levy,, and B. Demple. 2001. A sox RS-constitutive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (serovar Typhimurium). Antimicrob. Agents Chemother. 45: 38 43.
112. Lee, E. H.,, E. Collatz,, I. Podglajen,, and L. Gutmann. 1996. A rob-like gene of Enterobacter cloacae affecting porin synthesis and susceptibility to multiple antibiotics. Antimicrob. Agents Chemother. 40: 2029 2033.
113. Lewis, K.,, D. C. Hooper,, and M. Ouellette. 1997. Multidrug resistance pumps provide broad defense. ASM News 63: 605 610.
114. Li, X . Z.,, D. M. Livermore,, and H. Nikaido. 1994. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob. Agents Chemother. 38: 1732 1741.
115. Li, X . Z.,, H. Nikaido,, and K. Poole. 1995. Role of mexAmexB- oprM in antibiotic efflux in Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 39: 1948 1953.
116. Li, X . Z.,, L. Zhang,, and K. Poole. 2000. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45: 433 436.
117. Linde, H. J.,, F. Notka,, M. Metz,, B. Kochanowski,, P. Heisig,, and N. Lehn. 2000. In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob. Agents Chemother. 44: 1865 1868.
118. Liu, J.,, H. E. Takiff,, and H. Nikaido. 1996. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J. Bacteriol. 178: 3791 3795.
119. Lomovskaya, O.,, F. Kawai,, and A. Matin. 1996. Differential regulation of the mcb and emr operons of Escherichia coli: role of mcb in multidrug resistance. Antimicrob. Agents Chemother. 40: 1050 1052.
120. Lomovskaya, O.,, A. Lee,, K. Hoshino,, H. Ishida,, A. Mistry,, M. S. Warren,, E. Boyer,, S. Chamberland,, and V. J. Lee. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43: 1340 1346.
121. Lomovskaya, O.,, and K. Lewis. 1992. emr, an Escherichia coli locus for multidrug resistance. Proc. Natl. Acad. Sci. USA 89: 8938 8942.
122. Lomovskaya, O.,, K. Lewis,, and A. Matin. 1995. EmrR is a negative regulator of the Escherichia coli multidrug resistance pump EmrAB. J. Bacteriol. 177: 2328 2334.
123. Lomovskaya, O.,, M. S. Warren,, A. Lee,, J. Galazzo,, R. Fronko,, M. Lee,, J. Blais,, D. Cho,, S. Chamberland,, T. Renau,, R. Leger,, S. Hecker,, W. Watkins,, K. Hoshino,, H. Ishida,, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45: 105 116.
124. Mao, W. M.,, M. S. Warren,, A. Lee,, A. Mistry,, and O. Lomovskaya. 2001. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 45: 2001 2007.
125. Margolles, A.,, M. Putman,, H. W. Van Veen,, and W. N. Konings. 1999. The purified and functionally reconstituted multidrug transporter LmrA of Lactococcus lactis mediates the transbilayer movement of specific fluorescent phospholipids. Biochemistry 38: 16298 16306.
126. Markham, P. N. 1999. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob. Agents Chemother. 43: 988 989.
127. Markham, P. N.,, M. Ahmed,, and A. A. Neyfakh. 1996. The drug-binding activity of the multidrug-responding transcriptional regulator BmrR resides in its C-terminal domain. J. Bacteriol. 178: 1473 1475.
128. Markham, P. N.,, and A. A. Neyfakh. 1996. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 2673 2674.
129. Martinez-Martinez, L.,, I. Garcia,, S. Ballesta,, V. J. Benedi,, S. Hernandez-Alles,, and A. Pascual. 1998. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 42: 1850 1852.
130. Martinez-Martinez, L.,, A. Pascual,, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351: 797 799.
131. Maseda, H.,, K. Saito,, A. Nakajima,, and T. Nakae. 2000. Variation of the mexT gene, a regulator of the MexEF-OprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 192: 107 112.
132. Maseda, H.,, H. Yoneyama,, and T. Nakae. 2000. Assignment of the substrate-selective subunits of the MexEFOprN multidrug efflux pump of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 658 664.
133. Masuda, N.,, and S. Ohya. 1992. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 36: 1847 1851.
134. Masuda, N.,, E. Sakagawa,, S. Ohya,, N. Gotoh,, and T. Nishino. 2001. Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to 0-lactams due to reduced expression of the AmpC 0-lactamase. Antimicrob. Agents Chemother. 45: 1284 1286.
135. Masuda, N.,, E. Sakagawa,, S. Ohya,, N. Gotoh,, H. Tsujimoto,, and T. Nishino. 2000. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 2242 2246.
136. Masuda, N.,, E. Sakagawa,, S. Ohya,, N. Gotoh,, H. Tsujimoto,, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 3322 3327.
137. Mazzariol, A.,, Y. Tokue,, T. M. Kanegawa,, G. Cornaglia,, and H. Nikaido. 2000. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob. Agents Chemother. 44: 3441 3443.
138. Miller, P. F.,, L. Gambino,, M. C. Sulavik,, and S. J. Gracheck. 1994. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob. Agents Chemother. 38: 1773 1779.
139. Mine, T.,, Y. Morita,, A. Kataoka,, T. Mizushima,, and T. Tsuchiya. 1999. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43: 415 417.
140. Miyamae, S., H, Nikaido, Y. Tanaka, and F. Yoshimura. 1998. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42: 2119 2121.
141. Miyamae, S.,, O. Ueda,, F. Yoshimura,, J. Hwang,, Y. Tanaka,, and H. Nikaido. 2001. A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob. Agents Chemother. 45: 3341 3346.
142. Moore, R. A.,, B. Beckthold,, S. Wong,, A. Kureishi,, and L. E. Bryan. 1995. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39: 107 111.
143. Morita, Y .,, K. Kodama,, S. Shiota,, T. Mine,, A. Kataoka,, T. Mizushima,, and T. Tsuchiya. 1998. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents Chemother. 42: 1778 1782.
144. Morrissey, I.,, and J. T. George. 2000. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J. Antimicrob. Chemother. 45: 101 106.
145. Munoz, R.,, and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40: 2252 2257.
146. Munoz-Bellido, J. L.,, M. A. Manzanares,, J. A. Andres,, M. N. Zufiaurre,, G. Ortiz,, M. S. Hernandez,, and J. A. Garcia- Rodriguez. 1999. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA . Antimicrob. Agents Chemother. 43: 354 356.
147. Nagai, K.,, T. A. Davies,, B. E. Dewasse,, M. R. Jacobs,, and P. C. Appelbaum. 2001. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 48: 365 374.
148. Nagai, K.,, T. A. Davies,, G. A. Pankuch,, B. E. Dewasse,, M. R. Jacobs,, and P. C. Appelbaum. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 2740 2746.
149. Nakanishi, N.,, S. Yoshida,, H. Wakebe,, M. Inoue,, and S. Mitsuhashi. 1991. Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob. Agents Chemother. 35: 1053 1059.
150. Nakano, M.,, T. Deguchi,, T. Kawamura,, M. Yasuda,, M. Kimura,, Y. Okano,, and Y. Kawada. 1997. Mutations in gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41: 2289 2291.
151. Neyfakh, A. A. 1992. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob. Agents Chemother. 36: 484 485.
152. Neyfakh, A. A.,, C. M. Borsch,, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37: 128 129.
153. Ng, E. Y.,, M. Trucksis,, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38: 1345 1355.
154. Ng, E. Y.,, M. Trucksis,, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus . Antimicrob. Agents Chemother. 40: 1881 1888.
155. Nikaido, H.,, and D. G. Thanassi. 1993. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob. Agents Chemother. 37: 1393 1399.
156. Nishino, Y.,, T. Deguchi,, M. Yasuda,, T. Kawamura,, M. Nakano,, E. Kanematsu,, S. Ozeki,, and Y. Kawada. 1997. Mutations in the gyrA and parC genes associated with fluoroquinolone resistance in clinical isolates of Citrobacter freundii. FEMS Microbiol. Lett. 154: 409 414.
157. Oethinger, M.,, W. V. Kern,, A. S. Jellen-Ritter,, L. M. McMurry,, and S. B. Levy. 2000. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 44: 10 13.
158. Oethinger, M.,, I. Podglajen,, W. V. Kern,, and S. B. Levy. 1998. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli . Antimicrob. Agents Chemother. 42: 2089 2094.
159. Ohki, R.,, and M. Murata. 1997. bmr3, a third multidrug transporter gene of Bacillus subtilis. J. Bacteriol. 179: 1423 1427.
160. Ohshita, Y.,, K. Hiramatsu,, and T. Yokota. 1990. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem. Biophys. Res. Commun. 172: 1028 1034.
161. Okazaki, T.,, and K. Hirai. 1992. Cloning and nucleotide sequence of the Pseudomonas aeruginosa nfxB gene, conferring resistance to new quinolones. FEMS Microbiol. Lett. 76: 197 202.
162. Okuda, J.,, E. Hayakawa,, M. Nishibuchi,, and T. Nishino. 1999. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants. Antimicrob. Agents Chemother. 43: 1156 1162.
163. Okusu, H.,, D. Ma,, and H. Nikaido. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178: 306 308.
164. Onodera, Y.,, and K. Sato. 1999. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob. Agents Chemother. 43: 2423 2429.
165. Pan, X. S.,, J. Ambler,, S. Mehtar,, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40: 2321 2326.
166. Pan, X . S.,, and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178: 4060 4069.
167. Pan, X . S.,, and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41: 471 474.
168. Pan, X . S.,, and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42: 2810 2816.
169. Pan, X . S.,, G. Yague,, and L. M. Fisher. 2001. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob. Agents Chemother. 45: 3140 3147.
170. Paulsen, I. T.,, M. H. Brown,, T. G. Littlejohn,, B. A. Mitchell,, and R. A. Skurray. 1996. Multidrug resistance proteins QacA and QacB from Staphylococcus aureus: membrane topology and identification of residues involved in substrate specificity. Proc. Natl. Acad. Sci. USA 93: 3630 3635.
171. Paulsen, I. T.,, M. H. Brown,, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60: 575 608.
172. Pearson, J. P.,, C. Van Delden,, and B. H. Iglewski. 1999. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J. Bacteriol. 181: 1203 1210.
173. Perichon, B.,, J. Tankovic,, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41: 1166 1167.
174. Pesci, E. C.,, J. B. Milbank,, J. P. Pearson,, S. McKnight,, A. S. Kende,, E. P. Greenberg,, and B. H. Iglewski. 1999. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 96: 11229 11234.
175. Pestova, E.,, R. Beyer,, N. P. Cianciotto,, G. A. Noskin,, and L. R. Peterson. 1999. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob. Agents Chemother. 43: 2000 2004.
176. Piddock, L. J., , and R. Wise. 1986. The effect of altered porin expression in Escherichia coli upon susceptibility to 4- quinolones. J. Antimicrob. Chemother. 18: 547 549.
177. Piddock, L. J. V.,, D. G. White,, K. Gensberg,, L. Pumbwe,, and D. J. Griggs. 2000. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44: 3118 3121.
178. Poole, K. 1994. Bacterial multidrug resistance—emphasis on efflux mechanisms and Pseudomonas aeruginosa. J. Anti microb. Chemother. 34: 453 456.
179. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob. Agents Chemother, 44: 2233 2241.
180. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob. Agents Chemother. 44: 2595 2599.
181. Poole, K.,, N. Gotoh,, H. Tsujimoto,, Q. X. Zhao,, A. Wada,, T. Yamasaki,, S. Neshat,, J. I. Yamagishi,, X . Z. Li,, and T. Nishino. 1996. Overexpression of the mexC-mexD-opr] efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21: 713 724.
182. Poole, K.,, K. Krebes,, C. McNally,, and S. Neshat. 1993. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J. Bacteriol. 17' 5: 7363 7372.
183. Poole, K.,, K. Tetro,, Q. X. Zhao,, S. Neshat,, D. E. Heinrichs,, and N. Bianco. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40: 2021 2028.
184. Pumbwe, L.,, and L. J. V. Piddock. 2000. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44: 2861 2864.
185. Putman, M.,, L. A. Koole,, H. W. Van Veen,, and W. N. Konings. 1999. The secondary multidrug transporter LmrP contains multiple drug interaction sites. Biochemistry 38: 13900 13905.
186. Putman, M.,, H. W. Van Veen,, J. E. Degener,, and W. N. Konings. 2001. The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology 147: 2873 2880.
187. Putman, M.,, H. W. Van Veen,, and W. N. Konings. 2000. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64: 672 693.
188. Rahman, M.,, G. Mauff,, J. Levy,, M. Couturier,, G. Pulverer,, N. Glasdorff,, and J. P. Butzler. 1994. Detection of 4- quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob. Agents Chemother. 38: 2488 2491.
189. Rella, M.,, and D. Haas. 1982. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob. Agents Chemother. 22: 242 249.
190. Renau, T. E.,, R. Leger,, E. M. Flamme,, J. Sangalang,, M. W. She,, R. Yen,, C. L. Gannon,, D. Griffith,, S. Chamberland,, O. Lomovskaya,, S. J. Hecker,, V. J. Lee,, T. Ohta,, and K. Nakayama. 1999. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem. 42: 4928 4931.
191. Revel, V.,, E. Cambau,, V. Jarlier,, and W. Sougakoff. 1994. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother. 38: 1991 1996.
192. Reyna, F.,, M. Huesca,, V. Gonzalez,, and L. Y. Fuchs. 1995. Salmonella typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrob. Agents Chemother. 39: 1621 1623.
193. Robillard, N. J.,, and A. L. Scarpa. 1988. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob. Agents Chemother. 32: 535 539.
194. Roychoudhury, S.,, C. E. Catrenich,, E. J. Mcintosh,, H. D. McKeever,, K. M. Makin,, P. M. Koenigs,, and B. Ledoussal. 2001. Quinolone resistance in staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Antimicrob. Agents Chemother. 45: 1115 1120.
195. Sabourin, M.,, J. A. Byl,, S. E. Hannah,, J. L. Nitiss,, and N. Osheroff. 1998. A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. J. Biol. Chem. 273: 29086 29092.
196. San, M. J.,, C. Hernandez-Chico,, P. Pereda,, and F. Moreno. 1985. Cloning and mapping of the genetic determinants for microcin B17 production and immunity. J. Bacteriol. 163: 275 281.
197. Sander, P.,, E. De Rossi,, B. Boddinghaus,, R. Cantoni,, M. Branzoni,, E. C. Bottger,, H. Takiff,, R. Rodriguez,, G. Lopez,, and G. Riccardi. 2000. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol. Lett. 193: 19 23.
198. Senior, S.,, A. Schmidt,, E. Maier,, R. Benz,, W. Goebel,, and I. Gentschev. 1997. In vivo and in vitro studies on interactions between the components of the hemolysin (HlyA) secretion machinery of Escherichia coli. Mol. Gen. Genet. 256: 306 319.
199. Schmitz, F. J.,, A. C. Fluit,, M. Luckefahr,, B. Engler,, B. Hofmann,, J. Verhoef,, H. P. Heinz,, U. Hadding,, and M. E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus . J. Antimicrob. Chemother. 42: 807 810.
200. Schmitz, F. J.,, B. Hertel,, S. Scheuring,, J. Verhoef,, and A. C. Fluit. 1998. Correlation of norfloxacin MIC-values with mutations with the coding and promoter region of the norA gene in 42 unrelated clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42: 561 563.
201. Schmitz, F. J.,, B. Hofmann,, B. Hansen,, S. Scheuring,, M. Luckefahr,, M. Klootwijk,, J. Verhoef,, A. Fluit,, H. P. Heinz,, K. Kohrer,, and M. E. Jones. 1998. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob. Chemother. 41: 481 484.
202. Schmitz, F. J.,, M. E. Jones,, B. Hofmann,, B. Hansen,, S. Scheuring,, M. F. A. Luckefahr,, J. Verhoef,, U. Hadding,, H. P. Heinz,, and K. Kohrer. 1998. Characterization of grlA, grlBt gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42: 1249 1252.
203. Shen, L. L.,, W. E. Kohlbrenner,, D. Weigl,, and J. Baranowski. 1989. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme- DNA complexes. J. Biol. Chem. 264: 2973 2978.
204. Shultz, T. R.,, J. W. Tapsall,, and P. A. White. 2001. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob. Agents Chemother. 45: 734 738.
205. Sreedharan, S.,, M. Oram,, B. Jensen,, L. R. Peterson,, and L. M. Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J. Bacteriol. 172: 7260 7262.
206. Srikumar, R.,, X . Z. Li,, and K. Poole. 1997. Inner membrane efflux components are responsible for p-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa. J. Bacteriol. 179: 7875 7881.
207. Sulavik, M. C.,, M. Dazer,, and P. F. Miller. 1997. The Salmonella typhimurium mar locus: molecular and genetic analyses and assessment of the requirement for virulence. J. Bacteriol. 179: 1857 1866.
208. Sulavik, M. C.,, C. Houseweart,, C. Cramer,, N. Jiwani,, N. Murgolo,, J. Greene,, B. DiDomenico,, K. J. Shaw,, G. H. Miller,, R. Hare,, and G. Shimer. 2001. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob. Agents Chemother. 45: 1126 1136.
209. Sun, L.,, S. Sreedharan,, K. Plummer,, and L. M. Fisher. 1996. NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Antimicrob. Agents Chemother. 40: 1665 1669.
210. Takahata, M.,, M. Yonezawa,, S. Kurose,, N. Futakuchi,, N. Matsubara,, Y. Watanabe,, and H. Narita. 1996. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 38: 543 546.
211. Takei, M.,, H. Fukuda,, R. Kishii,, and M. Hosaka. 2001. Target preference of 15 quinolones against Staphylococcus aureuSy based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45: 3544 3547.
212. Takenouchi, T.,, C. Ishii,, M. Sugawara,, Y. Tokue,, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39: 1414 1418.
213. Takiff, H. E.,, M. Cimino,, M. C. Musso,, T. Weisbrod,, R. Martinez,, M. B. Delgado,, L. Salazar,, B. R. Bloom,, and W. R. Jacobs, Jr. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. USA 93: 362 366.
214. Takiff, H. E.,, L. Salazar,, C. Guerrero,, W. Philipp,, W. M. Huang,, B. Kreiswirth,, S. T. Cole,, W. R. Jacobs, Jr.,, and A. Telenti. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38: 773 780.
215. Tanaka, M.,, Y. Onodera,, Y. Uchida,, and K. Sato. 1998. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimicrob. Agents Chemother. 42: 3044 3046.
216. Tanaka, M.,, Y. Onodera,, Y. Uchida,, K. Sato,, and I. Hayakawa. 1997. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41: 2362 2366.
217. Tanaka, T.,, T. Horii,, K. Shibayama,, K. Sato,, S. Ohsuka,, Y. Arakawa,, K. Yamaki,, K. Takagi,, and M. Ohta. 1997. RobA-induced multiple antibiotic resistance largely depends on the activation of the AcrAB efflux. Microbiol. Immunol. 41: 697 702.
218. Tankovic, J.,, F. Mahjoubi,, P. Courvalin,, J. Duval,, and R. Leclercq. 1996. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob. Agents Chemother. 40: 2558 2561.
219. Tankovic, J.,, B. Perichon,, J. Duval,, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40: 2505 2510.
220. Tavio, M. D.,, J. Vila,, J. Ruiz,, G. Amicosante,, N. Franceschini,, A. M. Martin-Sanchez,, and M. T. J. De Anta. 2000. In vitro selected fluoroquinolone-resistant mutants of Citrobacter freundii: analysis of the quinolone resistance acquisition. J. Antimicrob. Chemother. 45: 521 524.
221. Taylor, D. E.,, and A. S. S. Chau. 1997. Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob. Agents Chemother. 41: 665 671.
221a. Tran, J. H.,, and G. A. Jacoby. 2002. Mechanism of plasmid-mediated quinolone resistance. Proc. Natl. Acad. Sci. USA 99: 5638 5642.
222. Trees, D. L.,, A. L. Sandul,, W. L. Whittington,, and J. S. Knapp. 1998. I dentification of novel mutation patterns in the parC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae . Antimicrob. Agents Chemother. 42: 2103 2105.
222a. Truong-Bolduc, Q. C.,, X. Zhang,, and D. C. Hooper. 2003. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J. Bacteriol. 185: 3127 3138.
223. Van Veen, H. W.,, K. Venema,, H. Bolhuis,, I. Oussenko,, J. Kok,, B. Poolman,, A. J. M. Driessen,, and W. N. Konings. 1996. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc. Natl. Acad. Sci. USA 93: 10668 10672.
224. Varon, E.,, C. Janoir,, M. D. Kitzis,, and L. Gutmann. 1999. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43: 302 306.
225. Vila, J.,, J. Ruiz,, P. Goni,, and M. T. Jimenez de Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40: 491 493.
226. Wandersman, C.,, and P. Delepelaire. 1990. TolC, an Escherichia coli outer membrane protein required for hemolysin secretion. Proc. Natl. Acad. Sci. USA 87: 4776 4780.
226a. Wang, M.,, J. H. Tran,, G. A. Jacoby,, Y. Zhang,, F. Wang,, and D. C. Hooper. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai. Antimicrob. Agents Chemother., in press.
227. Wang, T.,, M. Tanaka,, and K. Sato. 1998. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob. Agents Chemother. 42: 236 240.
228. Wang, Y.,, W. M. Huang,, and D. E. Taylor. 1993. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob. Agents Chemother. 37: 457 463.
229. Wasserman, R. A.,, and J. C. Wang. 1994. Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme. J. Biol. Chem. 269: 20943 20951.
230. Weigel, L. M.,, G. J. Anderson,, R. R. Facklam,, and F. Tenover. 2001. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3517 3523.
231. Wetzstein, H. G.,, N. Schmeer,, and W. Karl. 1997. Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus Gloeophyllum striatum: identification of metabolites. Appl. Environ. Microbiol. 63: 4272 4281.
232. Wetzstein, H. G.,, M. Stadler,, H. V. Tichy,, A. Dalhoff,, and W. Karl. 1999. Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatum. Appl. Environ. Microbiol. 65: 1556 1563.
233. Willmott, C. J.,, S. E. Critchlow,, I. C. Eperon,, and A. Maxwell. 1994. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J. Mol. Biol. 242: 351 363.
234. Willmott, C. J., , and A. Maxwell. 1993. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37: 126 127.
235. Woolridge, D. P.,, N. Vazquez-Laslop,, P. N. Markham,, M. S. Chevalier,, E. W. Gerner,, and A. A. Neyfakh. 1997. Efflux of the natural polyamine spermidine facilitated by the Bacillus subtilis multidrug transporter Bit. J. Biol. Chem. 272: 8864 8866.
236. Xiong, A.,, A. Gottman,, C. Park,, M. Baetens,, S. Pandza,, and A. Matin. 2000. The EmrR protein represses the Escherichia coli emrRAB multidrug resistance operon by directly binding to its promoter region. Antimicrob. Agents Chemother. 44: 2905 2907.
237. Yamagishi, J. I.,, T. Kojima,, Y. Oyamada,, K. Fujimoto,, H. Hattori,, S. Nakamura,, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 1157 1163.
238. Yoneyama, H.,, A. Ocaktan,, N. Gotoh,, T. Nishino,, and T. Nakae. 1998. Subunit swapping in the Mex-extrusion pumps in Pseudomonas aeruginosa. Biochem. Biophys. Res. Commun. 244: 898 902.
239. Yoshida, H.,, M. Bogaki,, M. Nakamura,, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34: 1271 1272.
240. Yoshida, H.,, M. Bogaki,, M. Nakamura,, L. M. Yamanaka,, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35: 1647 1650.